Bayer AG (BAYRY) Given Consensus Recommendation of “Buy” by Brokerages
Shares of Bayer AG (OTCMKTS:BAYRY) have been assigned a consensus rating of “Buy” from the seven research firms that are presently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company.
A number of equities analysts have issued reports on BAYRY shares. Zacks Investment Research raised shares of Bayer from a “hold” rating to a “buy” rating and set a $148.00 target price on the stock in a report on Tuesday, September 19th. ValuEngine lowered shares of Bayer from a “buy” rating to a “hold” rating in a research note on Friday, September 22nd. Finally, BNP Paribas upgraded shares of Bayer from a “neutral” rating to an “outperform” rating in a research note on Monday, September 25th.
Bayer (OTCMKTS:BAYRY) opened at $30.86 on Monday. The company has a quick ratio of 1.29, a current ratio of 1.74 and a debt-to-equity ratio of 0.40. Bayer has a twelve month low of $24.56 and a twelve month high of $35.41. The stock has a market cap of $102,078.71, a PE ratio of 15.33, a price-to-earnings-growth ratio of 2.17 and a beta of 1.12.
Bayer Company Profile
Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology.
Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with MarketBeat.com's FREE daily email newsletter.